Gsk Plc (GSK) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access GSK quarterly Cash Flow →
This cash flow overview for Gsk Plc spans from Dec 31 2021 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income9,763.30
Depreciation & amortization1,393.06
Amortization of Other Assets1,659.54
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments11.87
Financial Instruments and Foreign Currency Transaction59.36
Income Taxes Paid Refund Classified As Operating Activities-1,202.00
Cash Flows From Used In Operating Activities Continuing Operations-
Cash Flows From Used In Operations Before Tax Discontinued Operations-
Income Taxes Paid Refund Classified As Operating Activities Discontinued Operations-
Adjustments For Reconcile Profit Loss2,654.00
Income taxes0.00
Purchase Of Intangible Assets Classified As Investing Activities2,159.51
Accounts Receivable0.00
Accounts Payable-808.66
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-11.87
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities7,783.20
Discontinued operations0.00
Net Cash flow from Operating Activities22,009.32
Investing Activities
Capital Expenditures1,778.26
Sale of Capital Items31.66
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Dividends Received Classified As Investing Activities0.00
Proceeds From Sales Of Interests In Associates-
Increase Decrease In Liquid Investments11.00
Interest Received Classified As Investing Activities154.00
Cash Flows From Used In Investing Activities Continuing Operations-
Cash Flows From Used In Investing Activities Discontinued Operations-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans342.99
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash FlowsFrom Losing Control Of Subsidiaries OrOther Businesses Classified As Investing Activities-35.62
Other Cash Payments To Acquire InterestsIn Joint Ventures Classified As Investing Activities0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-7,701.41
Discontinued operations0.00
Net Cash Flow from Investing Activities-5,584.12
Financing Activities
Short-term debt Net1,431.32
Other borrowing transactions0.00
Long-term debt - borrowings-1,846.86
Long-term debt - repayments2,610.67
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-7,056.33
Proceeds From Contributions Of Noncontrolling Interests-
Cash And Cash Equivalents If Different From Statement Of Financial Position3,403.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-4,861.20
Effect of exchange rate on cash flow-233.50
Discontinued operations0.00
Free Cash Flow23,819.24
Total Cash Flow4,481.28
4 historic quarters locked

Sign in to unlock the full Gsk Plc cash flow history.

About Gsk Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: March 6, 2026
  • Source: gsk-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001131399-26-000004

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License